Group items tagged

Pharmaceutical giant Bristol Myers Squibb has become the first pharmaceutical company in the UK to be accredited as a 'menopause friendly workplace'. The accreditation, awarded by an independent panel of judges, recognises employers who put diversity, inclusion and wellbeing at the centre stage of their business. Bristol Myers Squibb (BMS) said it rung in the changes in recognition of the fact that nearly eight of 10 menopausal women are in work and that this is the fastest growing demographic in the workforce. Panel members described BMS UK&I's application as "outstanding" and acknowledged "the huge strides they have made to help normalise the menopause" by fostering an inclusive culture.

Immuneering has entered into an agreement to expand its existing relationship with Bristol-Myers Squibb (BMS) for the use of Immuneering's proprietary computational biology methods to identify biological insights that would help in the discovery and development of medicines.

PBR Staff Writer Published 25 February 2014 Bristol-Myers Squibb (BMS) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational DCV Dual Regimen (daclatasvir and asunaprevir) for use as a combination therapy in the treatment of genotype 1b chronic hepatitis C infection (HCV).

AstraZeneca has completed the acquisition of Bristol-Myers Squibb's (BMS's) interests in the companies' diabetes alliance for $4.1bn.